Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Millie Long

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Inflammatory Bowel Diseases|January 13, 2022
High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel DiseaseJames D Lewis, Raymond K Cross, Millie Long, et al.
Gut|October 13, 2022
Response to Mansoor <i>et al</i>: 'epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'Kira L Newman, Kara Jencks, Victor Chedid, et al.
JMIR Research Protocols|December 15, 2022
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled TrialJordan Axelrad, Millie Long, Sara Horst, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 17, 2026
Increased osteoporosis burden and comparative antiresorptive effectiveness in inflammatory bowel disease: a real-world cohort studyAakash Desai, Himsikhar Khataniar, Hany Habib, et al.
The American Journal of Gastroenterology|July 18, 2023
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North StudyDavid Hudesman, Millie Long, Douglas Wolf, et al.
Inflammatory Intestinal Diseases|June 8, 2018
Asians have more perianal Crohn disease and ocular manifestations compared with white AmericansBharati Kochar, Edward L Barnes, Hans H Herfarth, et al.
The American Journal of Gastroenterology|March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 StudyScott D Lee, Severine Vermeire, Ryan Ungaro, et al.
The American Journal of Gastroenterology|July 18, 2023
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple SclerosisMillie Long, Raymond Cross, Jonathan Calkwood, et al.
Inflammatory Bowel Diseases|April 19, 2018
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel DiseaseMarla C Dubinsky, Raymond K Cross, William J Sandborn, et al.
Journal of Crohn'S & Colitis|June 13, 2024
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT ProgrammeSilvio Danese, Axel Dignass, Katsuyoshi Matsuoka, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Inflammatory Bowel Diseases|January 13, 2022
High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel DiseaseJames D Lewis, Raymond K Cross, Millie Long, et al.
Gut|October 13, 2022
Response to Mansoor <i>et al</i>: 'epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'Kira L Newman, Kara Jencks, Victor Chedid, et al.
JMIR Research Protocols|December 15, 2022
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled TrialJordan Axelrad, Millie Long, Sara Horst, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 17, 2026
Increased osteoporosis burden and comparative antiresorptive effectiveness in inflammatory bowel disease: a real-world cohort studyAakash Desai, Himsikhar Khataniar, Hany Habib, et al.
The American Journal of Gastroenterology|July 18, 2023
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North StudyDavid Hudesman, Millie Long, Douglas Wolf, et al.
Inflammatory Intestinal Diseases|June 8, 2018
Asians have more perianal Crohn disease and ocular manifestations compared with white AmericansBharati Kochar, Edward L Barnes, Hans H Herfarth, et al.
The American Journal of Gastroenterology|March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 StudyScott D Lee, Severine Vermeire, Ryan Ungaro, et al.
The American Journal of Gastroenterology|July 18, 2023
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple SclerosisMillie Long, Raymond Cross, Jonathan Calkwood, et al.
Inflammatory Bowel Diseases|April 19, 2018
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel DiseaseMarla C Dubinsky, Raymond K Cross, William J Sandborn, et al.
Journal of Crohn'S & Colitis|June 13, 2024
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT ProgrammeSilvio Danese, Axel Dignass, Katsuyoshi Matsuoka, et al.
Pageof 4